cover
Contact Name
Ratna Kumalasari
Contact Email
medicinus@dexagroup.com
Phone
+6287808191388
Journal Mail Official
medicinus@dexagroup.com
Editorial Address
Gedung Titan Center 5th Floor, Jl. Boulevard Bintaro B7/B1 No. 5, Bintaro Jaya Sektor 7, Pokdok Aren, Tangerang Selatan 15224
Location
Kota tangerang selatan,
Banten
INDONESIA
MEDICINUS
Published by PT Dexa Medica
ISSN : 1979391X     EISSN : 29638399     DOI : 10.56951
Core Subject : Health, Science,
Tujuan penerbitan jurnal Medicinus adalah untuk meningkatkan wawasan dan menambah khasanah pengetahuan para praktisi medis dan farmasis di bidang kedokteran dan kefarmasian. Ruang lingkup dari jurnal ilmiah ini adalah publikasi artikel-artikel ilmiah yang bisa disajikan dalam bentuk penelitian (research), laporan kasus (case report), teknologi dan klinis kefarmasian, serta ulasan literatur medis.
Articles 221 Documents
Jantung yang Tidak Tahu Sedang Diobati: Kardiotoksisitas Anthracycline dan Urgensi Kardio-Onkologi Raymond R. Tjandrawinata
MEDICINUS Vol. 39 No. 6 (2026): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56951/49s0cn95

Abstract

Anthracycline-based chemotherapy has long been a cornerstone in the management of various malignancies, however, this antineoplastic class carries a frequently under-recognized consequence in the form of subclinical cardiac injury thatdevelops long before clinical manifestations become apparent. Cardiotoxicity mediated by topoisomerase IIβ dysregulation and oxidative stress does not occur abruptly, but cumulatively, with an incidence of approximately 9% among exposed populations. The physiological paradox further complicates this phenomenon, as compensatory mechanisms may mask ongoing myocardial damage, allowing early intervention window to be frequently missed. This article argues that the traditional boundaries between oncology and cardiology are no longer sufficient, and that an integrated cardio-oncology approach, incorporating active cardiac surveillance as soon as the initiation of therapy, should be regarded as clinical necessity rather than merely a consultative option.